The present description relates to T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the present description relates to TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as IGF2BP3-001 have the amino acid sequence of KIQEILTQV (SEQ ID NO:1). The present description further relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.本說明書涉及結合腫瘤相關抗原 (TIA) 用於靶向癌細胞的 T 細胞受體 (TCR)，表達該受體的 T 細胞，該受體製備方法，以及使用該受體治療癌症的方法。特別是，本說明書涉及與含肽（例如 IGF2BP3-001）的 HLA I 類或 II 類分子結合的 TCR 及其變體，其具有 KIQEILTQV (SEQ ID NO:1) 的氨基酸序列。本說明書進一步涉及用於免疫治療方法的肽、蛋白質、核酸和細胞。特別是，本說明書涉及癌症的免疫療法。本說明書還涉及單獨使用或與其他腫瘤相關肽（刺激抗腫瘤免疫反應或體外刺激 T 細胞和轉入患者的疫苗複合物的活性藥物成分）聯合使用的腫瘤相關 T 細胞 (CTL) 肽表位。與主要組織相容性複合體 (MHC) 分子結合的肽或與此同類的肽也可能是抗體、可溶性 T 細胞受體和其他結合分子的靶標。
